Contineum Therapeutics

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies targeting the blood-brain barrier for neurological and inflammatory diseases. My training data contains limited but specific information about the company, primarily related to its IPO, pipeline candidates like PIPE-307 for multiple sclerosis, and its origins as a spin-out from Inception Sciences. The AI visibility is modest for a specialized biotech, with stronger recognition in financial contexts than clinical ones.